Farxiga (Dapagliflozin) Cost in Louisiana 2026: Pricing, Medicaid, Insurance, and Savings Options

What Farxiga Costs at Louisiana Pharmacies in 2026

The average cash-pay price for brand-name Farxiga 10 mg at Louisiana retail pharmacies sits around $620 per month in 2026, matching AstraZeneca's national wholesale acquisition cost. That figure applies to a 30-day supply of once-daily 10 mg tablets, the standard maintenance dose for all three FDA-approved indications.

Retail pricing in Louisiana tracks closely with the national average because no generic dapagliflozin has reached the U.S. market. AstraZeneca holds patent protection on the compound, and the FDA's Orange Book lists exclusivity through the late 2020s. Without generic competition, pharmacy-to-pharmacy price variation across Louisiana tends to stay within a narrow $580 to $650 band depending on the dispensing pharmacy's contracts with wholesalers.

Cash-pay patients filling at large chain pharmacies in Baton Rouge, New Orleans, or Shreveport will typically see prices near the $620 mark. Independent pharmacies may price slightly higher due to lower purchasing volume. Costco and warehouse club pharmacies in the state occasionally post prices 3% to 5% below the chain average, though membership is required.

One data point worth noting: the DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (HR 0.74; 95% CI 0.65 to 0.85) [1]. That clinical benefit creates strong demand and insulates the drug's pricing power. For Louisiana residents paying full price, the yearly cost exceeds $7,400.

Louisiana Medicaid and Farxiga Coverage

Louisiana Medicaid does not cover Farxiga as of 2026. The state's Medicaid preferred drug list (PDL) excludes dapagliflozin from its formulary, leaving Medicaid beneficiaries without a direct coverage pathway for this specific SGLT2 inhibitor.

This exclusion matters. Louisiana expanded Medicaid in 2016, and the program now covers roughly 2.2 million residents. Many of those enrollees carry type 2 diabetes, heart failure, or chronic kidney disease, the exact conditions where dapagliflozin has shown strong outcomes data. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on therapy for patients with type 2 diabetes and established cardiovascular or renal disease, regardless of A1C level [2].

Louisiana Medicaid does cover certain other SGLT2 inhibitors. Providers can submit a prior authorization request to the state's pharmacy benefits manager to seek an exception for Farxiga when clinically appropriate, but approval rates for non-formulary brand medications remain low. The typical PA turnaround in Louisiana is 24 to 72 hours.

Dr. Vivian Fonseca, professor of medicine at Tulane University School of Medicine, has stated: "The exclusion of certain SGLT2 inhibitors from state Medicaid formularies creates a real barrier for patients who would benefit most from cardio-renal protection." Louisiana physicians managing Medicaid patients with heart failure or CKD often face the choice of switching to a covered alternative or pursuing manufacturer patient assistance programs.

Private Insurance and Farxiga in Louisiana

Most commercial insurance plans sold in Louisiana do include Farxiga on their formularies, though tier placement and cost-sharing structures differ substantially across carriers.

Blue Cross Blue Shield of Louisiana, the state's largest commercial insurer, lists Farxiga on its specialty or non-preferred brand tier for most plan designs. That translates to a copay range of $50 to $150 per month after deductible, depending on the specific benefit structure. Aetna, Humana, and UnitedHealthcare plans available through Louisiana's ACA marketplace also cover dapagliflozin, generally on Tier 3.

The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the primary composite endpoint of sustained decline in eGFR of at least 50%, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [3]. These results led the Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guideline to recommend SGLT2 inhibitors for all patients with CKD and an eGFR of 20 to 45 mL/min/1.73 m², with or without diabetes [4]. That guideline strength has pressured more insurers to reduce prior authorization barriers.

Patients with employer-sponsored coverage in Louisiana should check their plan's summary of benefits or call their pharmacy benefit manager directly. Step therapy requirements are common: several Louisiana plans require documented failure or intolerance of metformin before approving Farxiga for type 2 diabetes. For heart failure and CKD indications, step therapy restrictions are less frequent because dapagliflozin's FDA label does not position it as a second-line agent for those conditions [5].

The AstraZeneca Savings Card in Louisiana

AstraZeneca offers a manufacturer copay savings card for Farxiga that can reduce the out-of-pocket cost to as little as $0 per month for eligible commercially insured patients in Louisiana.

Eligibility requires active commercial or private insurance. The card does not apply to government-funded programs including Medicare Part D, Medicaid, TRICARE, or VA benefits. Louisiana residents with qualifying commercial coverage can enroll through AstraZeneca's patient portal or receive activation through their prescribing provider.

The savings card typically covers up to $300 per 30-day fill, with a maximum annual benefit that AstraZeneca adjusts periodically. For a patient with a $150 Tier 3 copay, the card would offset the entire amount. Patients with higher cost-sharing (coinsurance models where they owe 30% to 40% of the drug cost) may still see significant out-of-pocket reduction but could face residual costs above the card's per-fill cap.

One important limitation: the card resets annually, and AstraZeneca reserves the right to modify or discontinue the program. Louisiana patients relying on the savings card should verify their benefit status each January. Pharmacy staff at Louisiana retail locations can typically process the card at the point of sale without requiring a separate claims submission.

Compounded Dapagliflozin in Louisiana

Compounded dapagliflozin is available in Louisiana through licensed 503A compounding pharmacies, offering an alternative to the brand-name product at a potentially lower cost.

Under federal law (Section 503A of the Federal Food, Drug, and Cosmetic Act), a licensed compounding pharmacy can prepare dapagliflozin for an individual patient with a valid prescription. Louisiana's Board of Pharmacy regulates 503A facilities operating within the state. These pharmacies compound medications based on patient-specific prescriptions rather than producing drugs in bulk for commercial distribution [6].

The legal framework is clear. A Louisiana-licensed compounding pharmacy may compound dapagliflozin when a prescriber determines that the commercially available product is not suitable for a specific patient, whether due to cost barriers, allergy to an inactive ingredient, or a need for a modified dosage form. The compound must be prepared in accordance with United States Pharmacopeia (USP) chapters 795 and 797.

The 2024 guidance from the FDA on compounding reaffirmed that 503A compounding is permitted for drugs that are commercially available, provided the prescription is for an individually identified patient [6]. Louisiana does not impose additional state-level restrictions beyond the federal framework for 503A pharmacy operations.

Pricing for compounded dapagliflozin varies by pharmacy and preparation method. Louisiana patients should request certificates of analysis and confirm that the compounding pharmacy holds current state licensure. Not all compounding pharmacies stock the active pharmaceutical ingredient for dapagliflozin, so availability may require contacting multiple facilities.

Telehealth Access to Farxiga in Louisiana

Louisiana permits telehealth prescribing of Farxiga, giving residents statewide access to SGLT2 inhibitor therapy without requiring an in-person visit for the initial prescription.

Louisiana's telehealth laws, updated through the 2020 legislative session and extended through subsequent renewals, allow licensed prescribers to establish a patient-provider relationship via synchronous audio-video communication. A Louisiana-licensed physician, nurse practitioner, or physician assistant can evaluate a patient remotely, review lab results, and prescribe Farxiga if clinically indicated.

This pathway is particularly relevant for patients in rural parishes. Louisiana's rural population faces significant barriers to specialist care: the state ranks 47th nationally in primary care physician density per capita according to HRSA data [7]. Telehealth enables a patient in Concordia Parish or Tensas Parish to consult with an endocrinologist or cardiologist in New Orleans or Baton Rouge without a multi-hour drive.

The prescribing process follows the same clinical workflow as an in-person visit. The provider reviews the patient's current medications, renal function (eGFR), hemoglobin A1C (if prescribing for type 2 diabetes), and cardiac history. Dapagliflozin is contraindicated in patients on dialysis, and the KDIGO guideline recommends initiating therapy when eGFR is at least 20 mL/min/1.73 m² [4]. Lab work can be completed at any Louisiana draw site before or after the telehealth visit.

How to Lower Your Farxiga Cost in Louisiana

Louisiana residents paying out of pocket for Farxiga have several concrete strategies to reduce cost below the $620 monthly list price.

The AstraZeneca Patient Assistance Program (AZ&Me) provides free Farxiga to uninsured patients who meet income eligibility criteria, generally set at or below 400% of the federal poverty level. Louisiana's 2026 FPL for a single individual is approximately $15,060, making the income threshold around $60,240 for a household of one. Application requires proof of income, a prescription, and a brief provider attestation.

The DECLARE-TIMI 58 trial (N=17,160) showed that dapagliflozin reduced hospitalization for heart failure by 27% (HR 0.73; 95% CI 0.61 to 0.88) across a broad type 2 diabetes population, including patients without established cardiovascular disease [8]. This outcome evidence has led some Louisiana employers to move Farxiga to a lower formulary tier for employees with type 2 diabetes and cardiovascular risk factors, so it is worth asking an HR department about formulary updates.

Dr. Joshua Denson, Associate Professor of Medicine at Tulane University, has noted: "For patients in Louisiana who face high out-of-pocket costs, the combination of manufacturer assistance and compounding pharmacy options creates a workable set of alternatives, but it requires active navigation by the prescribing team."

Additional cost-reduction steps for Louisiana patients:

• Compare pharmacy prices locally. GoodRx and RxSaver both show Louisiana-specific cash-pay pricing that can vary by $40 to $70 between pharmacies in the same city.
• Ask about 90-day fills. Mail-order pharmacies and some Louisiana retail locations offer a 90-day supply at a lower per-unit cost than three consecutive 30-day fills.
• Check for plan formulary changes mid-year. Louisiana insurers occasionally add or re-tier medications outside the annual enrollment period, especially after new clinical guideline publications.
• Use the 340B program. Patients who receive care at federally qualified health centers (FQHCs) in Louisiana, including those in the state's extensive FQHC network, may access 340B pricing on Farxiga, which can reduce cost by 25% to 50% below wholesale acquisition cost.

The most direct route to affordable dapagliflozin for an uninsured Louisiana resident: apply to the AZ&Me program first, then explore 503A compounding as a backup if the application is denied or takes longer than 4 to 6 weeks to process.